IL6 and Stroke: the primary result was the reduction of hs-CRP and IL-6 levels in a dose-dependent manner, associated with a reduced incidence of the composite outcome consisting in non-fatal myocardial infarction, non-fatal stroke, or cardiovascular death for the 150 mg and 300 mg dosages.